Is NeoGenomics (NEO) Stock Outpacing Its Medical Peers This Year?

A generic image of a pen and a calculator
Credit: Shutterstock photo

Investors focused on the Medical space have likely heard of NeoGenomics (NEO), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.

NeoGenomics is a member of our Medical group, which includes 840 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.

The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. NEO is currently sporting a Zacks Rank of #1 (Strong Buy).

Within the past quarter, the Zacks Consensus Estimate for NEO's full-year earnings has moved 28% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

Our latest available data shows that NEO has returned about 26.86% since the start of the calendar year. Meanwhile, the Medical sector has returned an average of -9.57% on a year-to-date basis. This means that NeoGenomics is performing better than its sector in terms of year-to-date returns.

Looking more specifically, NEO belongs to the Medical - Biomedical and Genetics industry, which includes 340 individual stocks and currently sits at #74 in the Zacks Industry Rank. This group has lost an average of 27.24% so far this year, so NEO is performing better in this area.

Investors with an interest in Medical stocks should continue to track NEO. The stock will be looking to continue its solid performance.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NeoGenomics, Inc. (NEO): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics

Investing Stocks

Latest Markets Videos


    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

    Learn More